A new antifungal medicine for skin and body-wide Candida auris infections
Development and evaluation of a second-generation fungerp for systemic and cutaneous C. auris infection
This project tests a new drug called SCY-247 to treat Candida auris that lives on the skin and can spread through the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11221402 on NIH RePORTER |
What this research studies
Researchers are developing SCY-247, a second-generation 'fungerp' antifungal, to target Candida auris on the skin and in the bloodstream. They will study how well the drug kills resistant C. auris strains and whether it can reach and clear skin reservoirs that help spread infection. Lab and preclinical models that mimic skin colonization and invasive disease will be used to measure activity and safety before any future patient testing. The aim is a single approach that can address both cutaneous carriage and systemic infections, including strains resistant to existing antifungal classes.
Who could benefit from this research
Good fit: People with confirmed Candida auris infections—especially those with skin colonization or invasive bloodstream infection not responding to current antifungals—would be the primary patients this work aims to help.
Not a fit: Patients without Candida auris infections or those whose infections are already well controlled by existing antifungals are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this could provide a new treatment that works against drug-resistant Candida auris on the skin and in the bloodstream.
How similar studies have performed: First-generation 'fungerp' drugs have shown antifungal activity and one has reached clinical use for certain Candida infections, but SCY-247 is a newer candidate designed to better target resistant C. auris.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Ghannoum, Mahmoud a — Case Western Reserve University
- Study coordinator: Ghannoum, Mahmoud a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.